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Abstract 
RED BLOOD CELL STAB ILIT Y IN UREMIC RATS 
Cec il ia Mermel MacCallum, Masters Degree 
A thes is subm itted in part ial fulfillment of the requ irements for the degree of 
Master of B iochem istry in the Department of B iochem istry, School of 
Med ic ine at the Med ical College of V irg in ia. 
V irg inia Commonwealth Un ivers ity, 1996 
Adv isor : Dr. R ichard Brandt, Ph. D . ,  Department of B iochemistry and 
Preventat ive Med ic ine 
Determ in ing the frag il ity of the red blood cell (RBC ) is important for 
the d iagnos is of and evaluat ion for treatment of several RBC d iseases . In part 
RBC product ion is controlled through the hormone erythropoe it in secreted by 
the k idney. In a prev ious study from th is laboratory, it was found that RBC 
were more stable in urem ic male rats compared to controls .  In th is 
exper iment, urem ia was induced in four groups of female rats through a two 
stage nephrectomy. The nephrectomy involved the removal of two-th irds of 
the left k idney, followed by the removal of the ent ire r ight k idney one week 
later. The animals were div ided into three groups; NX-(5/6 nephrectomy), SH ­
(sham surgery), and PF-(sham surgery, but were fed the same food we ight as 
the N X  an imals) .  The samples obta ined in T rial I and Tr ial I I  were d iv ided 
into two categor ies ; in it ial and final . The in it ial samples were collected 14 
days after the sham and five- s ixth nephrectomy surger ies.  The final samples 
lX 
were collected at the time of sacrifice. The samples obtained in Trial I I  
consisted only of initial samples, taken fourteen days after the five-sixth 
nephrectomy and sham surgeries were completed. The samples in Trial IV 
were final samples, obtained at the time of sacrifice. Decreasing hypotonic 
%N aCl solutions were used to determine the hemolysis of RBC from the rats. 
RBC hemolysis was determined spectrophotometrically by monitoring 
hemoglobin absorbance at 540nm in the supernatant fluid. Analytic precision 
experiments using multiple assays of the same blood sample for 50% RBC 
hemolysis showed a coefficient of variation of only 1. 1%. Analysis of the 
%N aCl at 50% RBC hemolysis did not differ significantly between the three 
groups of animals suggesting that although the NX animals were uremic, the 
RBC did not differ in stability to hypoosmotic shock. Future direction for this 
type of research will be extended to human studies where kidney failure 
patients (dialysis patients) can have both the age of the RBC and their 
fragility determined under therapy. 
The erythrocyte hemolysis peroxide test (HPT) was also performed on 
rat blood samples from Trial IV and on five human blood samples, in order to 
determine hemolysis in the RBC. A 2% H202 solution was used to determine 
RBC stability and %Hemolysis was calculated by dividing the value for 
hemolysis due to H202 by the 100% hemolysis value and multipliying by 100. 
Analysis of the %Hemolysis by HPT for each animal sample also showed no 
significant difference between the three subgroups of animals. Future 
direction for this type of research will be extended to include all four trials of 
animals as well as human studies involving patient's with kidney failure 
(dialysis patients). 
Introduction 
A. Objectives 
Renal failure can occur at any age and if untreated can result in the 
death of the patient. Kidney disease has a variety of causes, among which are 
bacterial infections, congenital defects, impaired renal blood flow, tumors, 
toxins and immunological injury ( 1). When the degree of acute renal failure is 
moderate, the major physiological effect is retention of salt and water. Edema 
results and eventually the patient will develop hypertension, usually with a 
blood pressure increase of 30 to 40 mm Hg. In severe cases of renal failure, 
uremic retention of waste products ensues and acidosis develops (2) .  The effect 
of renal failure on the body's physiological mechanisms are complex, 
widespread and can be quite deleterious. 
Hemolytic anemia is a common and severe complication of renal failure. 
In some manner the disease state compromises the structural integrity of the 
red blood cell (RBC) membrane (3). The mechanism underlying the decreased 
red cell survival in uremia has not been completely elucidated. In considering 
possible mechanisms for the premature destruction of the red cell it has been 
suggested that the hexose mono phosphate (HMP) shunt of uremic red cells 
might be defective (4). RBC due to their unique structure of high 
concentrations of polyunsaturated fatty acids, molecular oxygen and ferrous 
ions in the ligand state are particularly susceptible to oxidative damage, thus 
suggesting a second possible explanation for the increased destruction of RBC 
in renal failure patients (5). RBC have an elaborate antioxidant defense 
system, which includes enzymes such as superoxide dismutase and catalase 
among others, as well as nonenzymatic biological antioxidants such as 
ascorbic acid and tocopherols. However, in renal failure these systems seem to 
be overwhelmed resulting in greatly increased hemolysis in renal failure 
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patients and consequently the average 120 day life span of the mammalian 
RBC is significantly shortened (6). 
Determining the fragility of RBC is important for diagnosis of disease 
as well as evaluation of treatments. The experiments presented here were 
designed to help determine what if any effect an acute renal insult may have 
on the stability of the RBC. The five-sixth nephrectomy model of chronic 
uremia exhibits biochemical changes resembling those of the naturally 
occurring disease and was therefore used as the model for uremia in these 
experiments (7). Table 1 lists some of the biochemical changes that occur in 
five-sixth nephrectomised animals that are consistent with changes in 
naturally uremic subjects. The animals studied were female Sprague-Dawley 
rats and were divided into three separate experimental groups: nephrectomised 
(NX), sham (SH), and pairfed (PF) (7). The animals in the NX group received a 
five-sixth nephrectomy in a two stage procedure. The second group, PF, 
received sham surgeries in which the renal capsule was removed from both 
kidneys, to prevent damage to the adrenal gland, but no tissue was removed. 
The animals in the PF group were then individually matched to a NX animal 
and were fed by weight only what the NX animal was fed. The third animal 
group, SH, received sham surgeries and there were no restrictions as to the 
quantity of normal rat chow or water they were allowed to consume (7). Table 
2 is a summary of the criteria for the grouping of the experimental animals. 
The initial blood samples were drawn two weeks after the surgeries to 
determine the onset of uremia, although previous experiments have shown 
that rats receiving this protocol were uremic by this time (7,34, 35, 4 1). 
A modification of the method of Parpat et a1. where an increase in the 
hypotonic environment to determine the stability of the RBC was used (8 ,  9). 
The experimental basis for this model originates from the finding that when a 
red cell reaches a certain increased volume due to a specific hypotonic NaCl 
environment, the hemoglobin diffuses to satisfy the equilibrium inside and 
outside the cell, usually without rupturing the plasma membrane (8) .  The red 
cells in any given population differ in the volume at which the hemoglobin will 
diffuse out, the osmotic resistance of such cells is believed to be inversely 
proportional to the fragility of the cell ( 10). In the past decreasing 
concentrations from isotonic solutes of sodium chloride, sodium oxalate, sodium 
Table 1. Biochemical Changes That Occur in Five-Sixth 
Nephrectomised Animals ( 13,4 1,42) 
Anorexia 
Growth Retardation 
Increased Serum Cholesterol 
Increased Serum Urea 
Increased Serum Phosphate 
Increased Serum Potassium 
Decreased Serum Calcium 
Hyperparathyroidism 
3 
Table 2. Summary of Criteria Used for the Grouping of 
Experimental Animals 
NX- Five-sixth nephrectomised animals 
Animal received five-sixth nephrectomy 
No dietary restrictions, animals fed ad libitum 
SH- Sham animals 
Animals received surgery, renal capsule was removed 
from both kidney, but no tissue was excised 
No dietary restrictions, animals fed ad libitum 
PF - Pairled animals 
Animals received surgery, renal capsule was removed 
from both kidneys, but no tissue was excised 
PF animals were fed by weight what the NX animals consumed 
4 
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sulfate, or sapotoxin have been used to create the hypotonic environment 
needed to measure RBC resistance. These reagents have been reported to 
cause hemolysis in different manners ( 1 1). For example, certain of these 
chemicals cause the cell membrane to become more permeable, while others 
damage the membrane causing release of the hemoglobin. Decreasing the 
concentration of N aCI in small increments allows for precise determination of 
the amount of RBC membrane permeability and for the calculation of NaCI 
concentrations at 50% hemolysis by spectrometric measurement of the 
increase in supernatant fluid hemoglobin. 
RBC fragility was also determined in a group of five humans by the 
modified Parpat et al. method as well as by using a hydrogen peroxide oxidative 
hemolysis test (HPT) outlined by Lubin et al. for comparison purposes ( 12). 
Vitamin E serum levels were also determined in these samples for 
determination of correlation between antioxidant concentration and fragility. 
The HPT was also performed on a group of the five-sixth nephrectomised rats. 
The HPT has been used to determine RBC hemolysis due to the simplicity and 
reliability the procedure has demonstrated. In addition, the HPT has been 
shown to be easily replicated, thus making it an potentially excellent 
experimental tool. 
B. Background 
1. Chronic Renal Failure 
Progressive kidney failure disturbs renal metabolic and excretory 
function which eventually has deleterious effects on many systems in the body 
( 13). Some features of renal failure in humans include; edema, acidosis, 
hypertension, hyperlipidemia, osteomalacia, azotemia and anemia ( 15). The 
five-sixth nephrectomy served as a model for chronic renal failure in these 
experiments. 
In humans, renal failure and the decrease in a large number of nephrons, 
results in the still functioning nephrons becoming severely overloaded. First, 
the blood flow through the glomerulus and the amount of filtrate formed by 
each functioning nephron increases 50 to 100 percent (2). Second, as 
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illustrated in Figure 1, while kidney shutdown increases, large quantities of 
excretory substances, such as urea, sulfates, uric acid, phosphates, water, 
sodium, and creatinine accumulate in the extracellular fluid. Bicarbonate will 
tend to decrease in the extracellular fluid as kidney failure progresses. These 
solutes greatly increase tubular loads of substances that are poorly 
reabsorbed, increasing as much as 1000 percent per nephron (2). Therefore, 
only a small fraction of the tubular solutes are reabsorbed, and the remaining 
solutes act as a osmotic diuretic, resulting in rapid flushing of tubular fluid 
through the tubules. The increased concentration of different substances in the 
extracellular fluid and the decrease in concominant tubular solute 
reabsorption, will lead to generalized edema, and acidosis (2). 
Through the normal metabolic processes there is an excess of 50 to 80 
mmoles of metabolic acid produced in one day over that of metabolic alkali (2). 
During kidney failure, acid begins to rapidly accumulate in the body fluids. 
Normally, the physiological buffers can buffer a total of 500 to 1000 mmoles of 
acid without lethal decrease of the extracellular fluid pH. In addition, the 
phosphate compounds in the bones can buffer a few thousand mmoles of the 
acid. However, under the conditions of renal failure, the buffering capacity is 
eventually used up and the extracellular pH falls drastically and severe 
acidosis results (2). 
The pathogenesis of hypertension in chronic renal failure is multi-
, faceted ( 14). Excessive renin secretion in relation to the sodium volume 
balance is a very important factor. There also exists some evidence that there 
are functional abnormalities of the sympathetic nervous system in uremic 
animals and humans. Stimulation of renal afferent nerves by uremic toxins 
such as urea evokes reflex increases in sympathetic nerve activity and blood 
pressure. Thus, chronic stimulation of renal afferent nerves may lead to 
sympathetic over activity and hypertension ( 15). 
Cardiovascular disease accounts for up to 50% of all patients with 
chronic renal failure and is a major cause of morbidity among that population 
( 16). Many factors contribute to the high prevalence of atherosclerosis in renal 
insufficiency including, hypertension, hyperlipidemia, vascular calcification, 
and endothelial injury. There is no single pathogenic mechanism for 
hyperlipidemia since abnormalities in lipoprotein metabolism result from 
Figure 1 (2) 
Change in Extracellular Constituents With Increasing Kidney Failure. 
As kidney failure progresses, represented on the x axis, some 
extracellular fluid constituents increase and some decrease as 
indicated by the y axis. As shown in this figure, non-protein nitrogen, 
potassium, water, sodium, hydrogen ions and phenols increase in the 
extracellular fluid. Bicarbonate decreases in the extracellular fluid as 
kidney failure progresses. 
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several causes ( 16). 
Hypertriglyceridemia, resulting from decreased clearance of very low­
density lipoproteins however, is the most common abnormality described. In 
addition to alterations in lipoprotein concentrations, abnormalities in lipid and 
apoprotein composition of lipoproteins are also factors. The activity of 
important apoproteins may be reduced and the activities of key enzymes in 
lipoprotein metabolism may also be decreased ( 16). 
The disruption in metabolic and excretory functions caused by chronic 
renal failure will eventually lead to renal osteodystrophy ( 13). Osteodystrophy 
is described in two ways; either as osteitis fibrosa a high turnover bone disease, 
or as osteomalacia, a low turnover bone disease ( 13). Osteitis fibrosa is caused 
by continually increased serum levels of PTH accompanied with an elevated 
number and size of osteoclasts, increased osteoblast activity, and enhanced 
resorption of bone. Osteomalacia results from vitamin D deficiency or from 
hypocalcemia ( 13). Vitamin D (D3. cholecalceferol) must be converted by a two 
stage hydroxylation, first in the liver and then in the kidney, into 1,25-
dihydroxycholecalciferol before it can promote calcium absorption from the 
intestine. Consequently, serious damage to the kidney as in renal failure, 
greatly reduces the availability of calcium to the bones and osteoblast activity 
is markedly decreased with ensuing decrease in bone formation (2). 
Excessive bleeding is also an important complication of uremia. Recent 
, animal experiments suggest that this bleeding tendency in uremia is due to an 
excessive formation of nitric oxide, an endogenous vasoactive molecule which 
also inhibits platelet function ( 17). Profound abnormalities in the coagulation 
system are characteristic of uremia, precise pathophysiology of the problem is 
still poorly understood ( 18). 
A decrease in red blood cell survival seems to be a common factor 
amongst patients with renal failure, consequently a patient with chronic renal 
failure almost always develops anemia ( 19). The kidneys normally secrete 
erythropoietin which stimulates the bone marrow to produce red cells (2). The 
erythrocyte has no nucleus, endoplasmic reticulum, mitochondria or other 
organelles required for cell maintenance, and consequently has a short lifespan 
of only about 120 days in the human. As erythrocytes age, changes in their 
plasma membrane make them susceptible to recognition and ingestion by 
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macrophages in the spleen, marrow and liver (2). Damaged kidneys are unable 
to form sufficient quantities of erythropoietin, which leads to diminished RBC 
production and consequent anemia. However, other factors may play a role in 
causing the anemia such as the high plasma concentrations of urea, hydrogen 
ions and other waste products (2). 
2. Oxidative damage in the Red Blood Cell 
Oxidative damage to cell components has been established as a factor in 
various pathological conditions (Table 3), including renal failure. RBC are 
particularly susceptible to oxidative damage as a result of the high 
polyunsaturated fatty acid (PUFA) content of their membranes and high 
cellular concentrations of hemoglobin and oxygen with hemoglobin being a 
potentially powerful promoter of oxidative processes (4). In addition during 
their relatively short lives in which no protein synthesis occurs, the RBC 
whose principal function it is to carry oxygen to and from the tissues and 
organs and to return carbon dioxide to the lungs (20), comes in close contact 
with free radicals from various sources: (1) the normal oxidation of hemoglobin, 
which ultimately produces the very reactive superoxide radical; (2) oxidation­
reduction of drugs or (3) xenobiotics that are transported by the blood (2 1). In 
healthy RBC significant oxidative damage is prevented by a very efficient 
antioxidant system (Table 4), consisting of a number of antioxidant compounds 
and enzymes including catalase, superoxide dismutase, glutathione with a 
regenerating system, glutathione peroxidase, and vitamin E, as well as 
effective compartmentalization of RBC components (6, 20). However, in 
disease states such as uremia, these antioxidant defense systems can be 
overwhelmed and the RBC becomes susceptible to oxidative damage. 
Even though mature RBC do not have a nucleus, mitochondria or 
endoplasmic reticulum, they do have cytoplasmic enzymes capable of 
metabolizing glucose and forming small amounts of adenosine triphosphate 
(ATP). ATP is used by the RBC in several ways: ( 1) helping to maintain the 
pliability of the membrane, (2) maintaining membrane transport of ions, (3) 
keeping the iron of the cell's hemoglobin in the ferrous form and (4) preventing 
oxidation of the proteins in the cell (2). With time, however, these metabolic 
Table 3. Pathological Conditions in Which Oxidative 
Damage is a Factor (3 1) 
1. Hemolytic anemia 
2. Retinopathy 
3. Atherosclerosis 
4. Cancer 
5. Rheumatoid arthritis 
6. Reoxygenation injury 
7. Drug-associated toxicity 
8. Viral infections 
1 1  
Table 4. Some Significant Red Blood Cell Antioxidant Compounds and 
Enzymes Commonly found in Healthy Red Blood Cells (3 1,32,33) 
1.Vitamin E 
2. Catalase 
3. Glutathione Peroxidase 
4. Ascorbate 
5. Selenium 
6. Beta Carotene 
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processes become less act ive and the cells become more frag ile.  Once the RBC 
membrane becomes too fra gile, it w ill rupture when the cell passes through 
t ight reg ions of the c irculat ion (2). The spleen, due to the small spaces between 
the structural trabeculae of the red pulp, is a common s ite for RBC 
fragmentat ion and cell death. 
a. Generation of Reactive species in the RBC 
RBC are cont inuously exposed to react ive oxygen spec ies from both 
internal and external sources . With in the cytosol of the RBC, under 
phys iolog ical cond it ions, it is est imated that as much as 3% of th e total body 
hemoglob in (Hb-Fe +2 ) is converted into methemoglob in (Hb-Fe +3 ) each day, 
as a result, the convers ion of oxyhemoglob in to methemoglob in serves as a 
constant source of superox ide rad icals (5). Superox ide rad icals w ill 
spontaneously or enzymat ically d is mutate y ield ing hydrogen perox ide.  The 
presence of both perox ide and the sup erox ide rad ical generates hydroxyl 
rad icals as shown in equation one (5): 
(eqn 1 )  
It has recently been found that in systems generat ing superox ide 
rad icals and perox ide, such as shown above in the RBC, the pres ence of iron 
w ill act as a catalyst in the format ion the hydroxyl rad ical as shown in the 
follow ing equat ions (5): 
. 02- + Fe +3 ---- > Fe +2 + 02 
. 02- + H02 " ---- > O2 + H202 
Fe +2 + H202 --- - > Fe +3 + . OH + OH-
(eqn 2) 
(eqn 3) 
(eqn 4) 
Thus, the react ion of hydrogen perox ide w ith ferrous iron w ill generate 
the hydroxyl rad ical at an increased rate (22). The hydroxyl rad ical (OH·)  is 
very damag ing to the RBC because it has the potent ial to init iate l ip id 
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peroxidation of the membrane, it can inactivate red cell enzymes and denature 
the hemoglobin molecule itself (2 1). 
-CH + OH· ---- > -C· + RH (eqn 5) 
The newly formed carbon centered radical reacts rapidly with oxygen: 
(eqn 6) 
Consequently a fatty acid side chain peroxyl radical (lipid peroxyl 
radical ) is formed which can attack adjacent fatty acid side chains and 
propagate lipid peroxidation (23). Thus, once initiated, the process of lipid 
peroxidation can be a elf-propagating. 
The interaction of hemoglobin in the RBC with xenobiotics or redox drugs 
can generate free radicals and oxidized or even denature hemoglobin (22). 
Heme bound oxygen can oxidize some compounds ,  as is the case with 
phenylhydrazine in the following manner (22): 
(eqn 7) 
Compounds such as quinones can be reduced by the heme iron: 
Hb+2 O2 + R ---- > Hb+3 + O2 + R· (eqn 8) 
Subsequently these drug radicals (R· ) can undergo secondary reactions 
with hemoglobin, molecular oxygen, or other cell constituents giving rise to 
superoxide radicals, peroxyl radicals and hydrogen peroxide, which can go onto 
induce membrane lipid peroxidation and hemolysis (22). 
h. Mechanisms of Oxidation in the RBC 
Polyunsaturated fatty acids are some of the most susceptible molecules to 
oxidative degradation present in nature (22). Membrane susceptibility to 
peroxidation is largely influenced by the amount of polyunsaturated fatty acids 
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present and their degree of unsaturation. Erythrocytes have an extremely 
heterogeneous composition of lipids in their membranes (Table 5) (25). During 
the lifespan of the RBC they undergo many structural and dimensional 
changes. Younger RBC contain appreciably more lipids than older cells,  which 
seem to lose cholesterol and phospholipid in the aging process (23). The 
erythrocyte, rich in polyunsaturated fatty acids is a readily available target for 
oxidation by free radicals. 
In lipid peroxidation, a primary reactive free radical , ( ·OH ) ,  like 
those in equations 5 and 6, interacts with a PUF A in the RBC membrane to 
initiate a complex series of reactions that result in a variety of degredation 
products that can result in cell lysis (25). PUFA in the erythrocyte membrane 
appear to be particularly sensitive to oxidative damage due to lowered bond 
dissociation energy of their allylic hydrogens (22). Initiation of peroxidation 
usually occurs by the attack of a free radical that is capable of abstracting a 
hydrogen from the RBC methlyenic carbon, for example, the hydroxy radical 
( ·OH) or the protonated form of the superoxide radical , perhydroxyl radical 
(H0 2 .) (22,26) : 
LH + Initiator ---- > L· + H202 (eqn 9) 
c. Antioxidant defenses of the RBC 
Since the mature mammalian erythrocyte is a non-nucleated cell it 
cannot synthesize protein, therefore it is more difficult for the cell to replace 
damaged components . Consequently a strong antioxidant defense system is 
mandatory for the RBC to survive in its aerobic environment (22. Hemoglobin 
is usually protected from oxidation by two processes: the reducing power of the 
RBC metabolism and the stable quartenary structure of the hemoglobin 
molecule (22). 
The RBC antioxidant defense systems can be found in two separate 
domains of the cell; one group is found in the cytosol and the second is found in 
the membrane itself. 
Superoxide dismutase is present in the RBC cytosol . The primary 
function of superoxide dismutase is to scavenge the superoxide radical 
Table 5. Lipids of the Erythrocyte (27) 
Lipid Type 
Cholesterol 
Free fatty acids, glycerides, 
sterol esters 
Phosphatidylcholine 
Phosphatidylserine 
Phosphatidylethanolamine 
Phosphatidylinositol 
Sphingomyelin 
Lysolecithin 
Phosphatidic acid 
Glycosphingolipids 
�Jmole x 10 - 10 
� 
3. 2 
< 0. 1 
1.2 
0.6 
1. 1 
0.03 
1.0 
0.04 
0.04 
0. 2 
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generated b y  the oxidation of hemoglobin to methemoglobin (22 ,22) .  The 
enzyme uses the superoxide radical as its substrate: 
( eqn 10) 
The resulting hydrogen peroxide is eliminated by glutathione and 
glutathione peroxidase: 
(eqn 1 1 ) 
A high GSHlGSSG ratio is maintained in normal cells through an 
enzymatic mechanism for reducing the GSSG back to GSH .  This is 
accomplished by the glutathione reductase enzymes , which catalyses this 
reaction (20,2 1 ,26) :  
GSSG + NADPH + H + ---- > 2 GSH + NADP+ (eqn 12)  
In addition to glutathione peroxidase, RBC also contain catalase, an 
enzyme that acts as a scavenger of hydrogen peroxide. The main reaction 
catalyzed by the enzyme in the following reaction: 
(eqn 13)  
The physiological role of catalase is  not clear .  However, it  has been 
demonstrated that catalase activity becomes important when the 
concentration of hydrogen peroxide is raised (22) .  
Vitamin E is the major RBC membrane-bound antioxidant defense. 
Vitamin E has been shown to scavenge both the oxygen radicals attacking 
from the outside of the RBC and suppress the oxidation of phospholipids 
induced by free radicals generated in the cytoplasm or lipid peroxyl radicals 
generated in the liposomal membrane itself ( 2 7 ) .  Vitamin E donates a 
hydrogen atom to peroxyl radicals converting them to hydroperoxides . The 
hydroperoxides are then decomposed to a non-toxic hydroxy compound by 
glutathione peroxidase (22) .  Thus, vitamin E plays a crucial role in protecting 
1 8  
the RBC membrane by interrupting the propagation of lipid peroxidation. A 
vitamin E radical is formed by the oxidation of the vitamin, however it is fairly 
stable because the unpaired electron on the oxygen atom can be delocalized 
into the aromatic ring structure of the tocopherol molecule or the tocopheroxyl 
radical can be reduced back to vitamin E by ascorbate (29) .  Although 
tocopherol and ascorbate are sequestered and separated in their respective 
lipid and aqueous phases, a significant decrease in lipid peroxidation is observed 
when both vitamins are present (30) .  Vitamin C by itself has been shown to be 
an sufficient antioxidant in the aqueous phase, but is much less effective when 
radicals are generated in the membrane itself, perhaps because it cannot 
penetrate the lipid phase in order to interact with the peroxyl radical (30) .  
Thus, the likely relationship between tocopherol and ascorbate that allows the 
combination of vitamins to be a more effective antioxidant defense, is that 
vitamin C reduces the tocopheroxyl radical back to alpha-tocopherol . This may 
be the mechanism whereby high concentrations of vitamin C can help protect 
against peroxidation (2 1 ) .  In addition, these antioxidants are renewable from 
dietary sources .  
C ompartmentalization in the RBC of various components is 
another important means of defense against oxidative stress (26) .  By keeping 
iron bound to transport or storage proteins cells prevent the conversion of 
H202 into the hydroxyl radical (26). 
(eqn 14) 
Hence, a major determinant of the nature of the damage done by the 
excess generation of reactive species may be the availability and location of 
the metal ion catalysts . 
3. Defect in the Hexose Monophosphate Shunt 
Glucose is the most important source of energy utilized by the RBC .  The 
RBC has no citric acid cycle and therefore is unable to further oxidize lactate or 
pyruvate formed during glycolysis (20) .  Inosine , fructose, mannose and 
galactose could be metabolized by the RBC for energy, but they are not 
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present i n  the plasma in sufficient concentration to be useful (20) .  Thus the 
RBC is dependent on the metabolism of glucose for most of its energy. 
Figure 2 illustrates the metabolic pathways utilized by the RBC (20) .  
Once glucose 6-phosphate is formed through the hexokinase reaction, it  may 
traverse two different pathways; the anaerobic pathway or the direct oxidative 
pathway (the hexose mono phosphate shunt). Under normal conditions, 90% of 
the glucose taken up by the RBC goes through the anaerobic pathway (20) .  
The main function of the HMP shunt in the RBC is to provide reducing 
equivalents for the reduction of oxidized glutathione (GSSG) to form reduced 
glutathione (GSH) (5,  20, 24) .  This is achieved through the formation of the 
reduced coenzyme NADPH, in the first two major steps of the pathway. GSSG 
is reduced by NAD PH using glutathione reductase as shown in eqn 12 (5, 20, 
22) .  
The HMP shunt through its production of NADPH functions to protect 
the RBC contents from oxidative denaturation through the regeneration of 
glutathione which is an essential component of the RBC antioxidant defense (6, 
20, 24, 25) .  Any defect in this metabolic pathway could lead to increased RBC 
destruction associated with oxidation of cellular glutathione and both the 
oxidative denaturation of hemoglobin into Heinz bodies and the oxidation of the 
cell membrane (4 ) .  Yawata et a1. (4)  suggested that a circulating factor 
accumulates in uremic patients that is believed to inhibit the RBC 
transketolase activity. This enzyme is involved in the recycling of glucose 
through the HMP shunt (4 ,  20 ) .  Another purposed mechanism behind the 
failure of the HMP shunt is a blockade in the main glycolytic pathway which 
would result in the accumulation of intermediates which in turn prevents 
shunting of metabolites into the main pathway, ultimately resulting in 
deficient recycling of glucose through the HMP shunt ( 19, 30) .The most likely 
glycolytic intermediates that have been shown to accumulate in uremic cells 
are fructose 1 ,6-bisphosphate and glyceraldehyde 3-phosphate, the central 
entrance points from the HMP shunt to the glycolytic pathway ( 30) .  The likely 
site of blockade then appears to involve phosphoglyceromutase (30 ) .  
Regardless of the site of the blockade of the HMP shunt, any defect in the 
shunt will severely impair the RBC capacity to defend against oxidative 
damage. 
Figure 2 (18) 
Metabolic Pathways Utilized by the Red Blood Cell . 
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Specifically glucose 6-phosphate can be metabolized by the anaerobic 
pathway (Glycolysis) or the hexose monophosphate shunt . 
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c. Summary 
The biochemical and molecular changes associated with renal failure are 
widespread and can be quite severe . Edema, acidosis, hypertension , 
hyperlipidemia, osteomalacia and anemia are common complications of renal 
failure . Among these, intermediates that have been shown to accumulate in 
uremic cells are fructose 1 ,6-bisphosphate and glyceraldehyde 3-phosphate, 
the central entrance points from the HMP shunt to the glycolytic pathway 
(30) .  Hemolytic anemia can be the most troublesome complication of uremia 
(2) .  The anemia associated with renal failure has been partially attributed to 
the shortened RB C survival . Erythrocytes are highly susceptible to 
peroxidation. Their membranes are rich in PUFA, they are continuously 
exposed to oxygen, and they contain a powerful transition metal catalyst, iron 
(22). Oxidation of the RBC is held in check by a powerful antioxidant defense 
system. However in renal failure, this system can be overwhelmed and result 
in greatly increased destruction of the RBC . In addition, defects in the HMP 
shunt commonly observed in renal failure, may shorten RBC survival (2) .  
Using the five-sixth nephrectomy model for uremia, we attempted to 
find out if indeed there was an increased destruction of the RBC in chronic 
uremia. The fragility of the RBC was determined by using a modification of the 
Parpat et al. method of increasing the hypotonic enviroment of the RBC (8, 9) .  
n 
Materials and Methods 
Red Blood Cell Stability in Uremic Rats Study 
A Animals 
Female rats were purchased from Charles River Breeding Laboratories 
(Wilmington, MA.). Animals were housed and fed individually in order to better 
monitor their food intake. The animal room had a controlled temperature of 2 1-
23 °C with a 14 hr light, 10 hr dark schedule. 
The animals were separated into three experimental groups : 
nephrectomised (NX), sham (SH), and pairfed (PF) ( 1 1 , 34, 35) .  The animals in 
the NX group received a five-sixth nephrectomy in a two stage procedure. The 
second group, PF, received sham surgeries in which the renal capsules were 
removed, to prevent damage to the adrenal gland, but no tissue was removed. 
The animals in the PF group were individually matched to a NX animal and 
were fed by weight only what the NX animal consumed . The third animal 
group, SH, received sham surgeries in which the renal capsule was removed, 
but no tissue was removed .  There were no restrictions as to the quantity of 
chow the SH animals were allowed to consume (10,  34, 35) .  
Four separate experimental trials are reported here; Trial I, Trial II, Trial 
III and Trial IV. The samples obtained in Trial I and Trial III are divided into 
two categories; initial and final. The initial samples were collected 14 days after 
the five-sixth nephrectomy was completed, and the final samples were 
collected at the time of sacrifice . The samples obtained in Trial II consisted 
only of initial samples and those in Trial IV were only final samples.  The 
animals in all four trials were Sprague-Dawley rats and were maintained as 
described above.  The criteria for division of animals into three subgroups: NX, 
SH and PF was the same in every trial and followed the guidelines described in 
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the preceding paragraph. 
B. Diet 
The animals were maintained on standard rodent laboratory chow 
( Ralston-Purina Co . ,  St. Louis , MO. )  in powdered form. The NX animals were 
fed chow ad libitum and the PF group were fed by weight the same quantity of 
food that the NX group consumed. The SH group were fed chow ad libitum. 
c. Age and Weight 
The mean weight of the rats in Trial I on arrival in the laboratory was 
182g and the range of ages were between 5 1-56 days . In Trial II the mean 
weight of the animals on arrival to the lab was 109g and the range of ages were 
between 36-39 days . In Trial I I I  the mean weight of the animals on arrival to 
the laboratory was 1 75g and the range of ages were between 5 1-56 days . In 
Trial IV, the mean weight of the animals on arrival to the laboratory was 160g 
and the range ages were between 45-50 days . 
On the day of sampling, approximately four weeks after arrival in the 
laboratory and approximately two weeks after surgical procedures were 
performed,  the individual weights of each animal were taken and they are 
shown in Table 6 in the Results Section. The mean weight of the animals in 
Trial I was 268g with a SEM of +/- 5 . 19 for a sample size of 22,  in Trial II the 
mean wieght was 220g with a SEM of +/- 3 .28 for a sample size of 28, in Trial 
I I I  the mean weight was 226g with a SEM of +/- 2 .81  for a sample size of 26, 
and in Trial IV the mean weight was 220g with a SEM of +/- 3 .83 for a sample 
size of 28 .  A significant increase in the animals weight was observed in all 
samples between the time of their arrival to the laboratory and the time of 
sampling. 
D. Experiments 
1. Surgical Procedure Used to Induce Uremia 
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The experimental model used in these trials, the five-sixth nephrectomy, 
has been shown to produce a state of mild to moderate uremia in Sprague 
Dawley rats by 14 days after the procedure 0 1, 35). 
a. Five-sixth Nephrectomy Procedure 
The five-sixth nephrectomy was performed by Drs. Krieg and Tokieda in 
the laboratory of Dr. Krieg, in a two stage procedure, on the NX subgroup of 
experimental animals . This same procedure was used in all four trials with the 
only exception being the type of anesthesia . In Trial I ,  II and IV all procedures 
were conducted using ether anesthesia, in Trial I I I ,  all procedures were 
conducted using brevital anesthesia. 
In the NX group of animals, in all four trials, the left kidney was exposed 
through a postero-Iateral incision 00, 34, 35) .  The renal capsule was removed 
to avoid inj uring the adrenal gland, the upper and lower thirds of the kidney 
were then excised ( 1 1 , 34, 35) .  Bleeding was controlled by applying manual 
pressure to the cut surfaces . The remaining third of the kidney was returned to 
the abdominal cavity, the wound sutured, and the animal was placed on a 
heating pad . One week later, the second stage of the nephrectomy was 
performe d .  The right kidney was exposed and also decapsulated to avoid 
damaging the adrenal gland. The entire right kidney was then removed 0 1, 34, 
35) .  
The SH and PF experimental animal groups received the same surgeries 
as described above, however, no tissue was removed. 
b. Catheterization 
Four days before sampling, a polyvinyl catheter ( Dural Plastics Ltd. ,  
Auburn, Australia) was inserted, under brevital anesthesia, through the right 
external j ugular vein into the right atrium ( 1 1 , 34, 35) .  To prevent removal of 
the catheter by the rat, the heparin filled catheter (50 IU/ml) was tunneled 
under the skin of the rat to exit dorsally ( 1 1 , 34, 35) .  The catheter was plugged 
and the animals were returned to their cages . 
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c .  Sampling 
Blood samples used to determine RBC hemolysis were taken on two 
separate occasions . The initial sample was taken 14 days after the five-sixth 
nephrectomy was completed ( 1 1 ) .  The final sample was drawn as the animal 
was sacrificed.  
On the day of blood sampling, a 50 cm polyvinyl extension was attached 
to the catheter by a piece of stainless steel tubing ( 1 1 ) .  The blood was 
withdrawn in heparin-treated syringes. The initial blood samples were replaced 
with saline ( 1 1) .  
2. Assay for Determination of RBC Hemolysis With Increasing 
Hypotonic NaCI Environment 
The procedure used to determine RBC hemolysis was a modified form of 
that described by Parpart et al . (8, 9, 34, 35) .  The degree of resistance of RBC 
to a decrease in the salt content of their environment has been used 
experimentally as one measure of their viability (8) .  The RB C has the 
tendency to undergo increasing hemolysis as the concentrations of a buffered 
sodium chloride solution is decreased from 0.9% . On the basis of these findings, 
in this experiment the concentrations of a buffered sodium chloride solution 
were decreased incrementally from 0 .8% to 0 . 1% and the 50% hemolysis point 
was determined by interpolation. 
a. Reagents 
Buffered NaCI Solutions ( 0 . 1% to 0 . 9% NaC!) were prepared using 
sodium chloride (Fisher), sodium phosphate ( Fisher),  sodium phosphate 
heptahydrate ( Fisher) and deionized water. The final pH of the solution was 
7 .4 .  
b.  Equipment 
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An IEC clinical centrifuge ( International Equipment Co. , Needam Hts.,  
MA. ) was used to separate the plasma from the RBC .  Pasteur pipettes 15cm 
long (Fisher) were used to remove the plasma. The plasma was then stored in 
2ml cryovials (Nalge ), at -70 °C in a freezer for future HPLC vitamin E 
analysis . Disposable pipettes 5 . 0ml (Fisher) were used to add 4 .0ml NaCl 
buffered solutions to 16 x 100mm disposable culture tubes ( Fisher) . 
Continuously adjustable digital microliter pipettes were used for the addition of 
the sample to the culture tubes . Incubation and shaking was accomplished 
through a water bath shaker ( Eberbach Corporation Ann Arbor, Mi . ) . The 
absorbance was determined using a Spectronic 20D ( Milton Ray Co. ) and B&L 
cuvettes . Hematocrit, whenever possible was measured to determine the 
percent of RBC per volume. 
c. Procedure 
For the initial sample, blood was withdrawn from the existing catheter 
into a heparin-treated syringe and approximately 1ml was removed for RBC 
hemolysis determination. The removed volume was replaced with 0 . 9% NaCl 
buffered saline solution. For the final sample , blood was removed from the 
abdominal aorta into a heparin-treated syringe and again approximately 1ml 
was removed for RBC hemolysis determination. 
The buffered saline was prepared using 9g NaCl, 2 . 7g Na2HP04·7H 20" 
0 .255g NaH2P04·H20 diluted with H20 to one liter ( 1% solution), pH 7 .4 .  The 
blood sample was centrifuged for five minutes and the plasma was removed 
and stored for further analysis .  The removed volume was replaced with 0 .3ml 
of 0 .9% buffered-NaCl, and mixed. 40� of blood was then added to 4ml of 0 . 10,  
0 .25, 0 .40, 0 .45, 0 .475,  0 .50,  0 .60, 0 .80% buffered NaCl.  The blood sample and 
buffered saline were then incubated at 30 °C for 0 .5  hr with gentle shaking. The 
sample was centrifuged for 6 minutes and the remaining RBC pellet 
sedemented on the bottom of the culture tube, with the hemoglobin in solution. 
A sample of the supernatant fluid was transferred to a cuvette with a Pasteur 
pipette and the absorbancy was determined at 540nm (the wavelength for 
hemoglobin absorbance) against a water blank. The coefficient of variation for 
this procedure was found to be only 1. 1%. 
d. Calculations 
1. Percent Hemolysis With Increasing Hypotonic NaCI 
Environment 
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In order to  calculate the %Hemolysis, the optical density (OD ) for the 
0 .8 (A) buffered %NaCI solution was subtracted from the OD of the remaining 
concentrations of buffered %NaCI solutions; 0 .60 ( B ), 0 . 50 (C) ,  0 .4  75(D),  0 .45 
(E) ,  0 .40 (F),  0 . 25 (G) and 0 . 10(H) .  The values for A, B, C, D, E, F, G and H 
were then divided by the value obtained for H (which represents OD for 100% 
hemolysis) and multiplied by 100 to determine percent hemolysis . Graphs were 
drawn with the ordinate, %Hemolysis and the abscissa, %NaCI concentrations. 
The 50% hemolysis point was interpolated from the graphs . Mean 50% 
hemolysis graphs for NX, PF and SH initial samples for animals in Trial II are 
shown in figures 3 ,4 or 5 in the Results Section. Mean 50% hemolysis graphs 
for NX, PF and SH final samples for animals in Trial III  are in figures 6, 7 or 8 
in the Results Section. 
2. Correlation Analysis 
For all animals in all four trials, the correlation coefficient for the linear 
regression was determined from graphs with the ordinate, concentrations of 
buffered %NaCI and the abscissa, %Hemolysis (calculated as previously 
discussed in Percent Hemolysis Section) (36) .  As shown in the Result Section, 
figures 9, 10 and 1 1  are examples of correlation graphs for SH, PF and NX 
initial samples in Trial 1 .  These graphs supplied the "r" or correlation coefficient 
value for each animal, the mean "r" value for each subgroup was calculated 
from the linear equation from the graph trial data, as well as a mean value for 
%NaCl concentration at 0% hemolysis and a mean value for %NaCI 
concentration at 50% hemolysis.  
Table 8 combines data from the linear correlation graphs completed for 
all initial and final samples in each trial with data calculated on these same 
samples from the %Hemolysis versus the %NaCI concentration graphs . The 
first column of table 8, (%NaCI concentration for 0% hemolysis ,  linear 
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correlation graph), is the %NaCI concentration at zero percent hemolysis as 
calculated from the linear correlation graphs for all samples, examples figures 
9, 10 ,  1 1 .  The second column , (%NaCI for 50% hemolysis, linear correlation 
graph), is the %NaCI concentration at 50% RBC hemolysis as calculated from 
the linear correlation graphs, example figures, 9, 10, and 1 1 . Finally, the third 
column, (%NaCI for 50% hemolysis, graphical interpolation), represents the 
concentration of %NaCI for 50% hemolysis as calculated from the sigmoidal 
graphs done on each animal with the abscissa of %Hemolysis and ordinate 
%NaCI, example figures 3-8 .  All analyses were performed using Statstix and 
Cricket Graph software on a Macintosh LC I I .  
3. Red Blood Cell Hemolysis Peroxide Test 
The erythrocyte hemolysis peroxide test (HPT) due to its reliability and 
ease with which it can be repeated has proven to be another excellent method 
by which to determine hemolysis in the RBC (36) .  The procedure used was 
preformed by a modification of the method of Lubin et al . (36). 
a. Experimental Subjects 
The experimental subj ects for the HPT consisted of two separate 
groups. Group one contained five adult female human subjects and Group two 
used female Sprague-Dawley rats . The rats were separated into three 
experimental groups; NX, SH and PF. All rat blood samples were from Trial IV 
of the RBC Stability in Uremic Rats Study and consisted only of final samples 
i .e .  collected at time of sacrifice. 
b. Reagents 
Buffered NaCI solution of 0 .9% was prepared using sodium chloride 
(Fisher), sodium phosphate heptahydrate (Fisher) sodium phosphate (Fisher), 
and deionized water. A 2% H202 solution was prepared by diluting 3mI of 30% 
H202 with 0 .9% buffered NaCI solution to a total volume of 50ml. 
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c .  Equipment 
The samples were placed in 16 X 100mm disposable culture tubes 
(Fisher) and an IEC clinical centrifuge ( International Equipment Co . ,  Needam 
Hts . ,  MA. ) was used to separate the plasma from the RBC .  Pasteur pipettes 
15cm long ( Fisher) were used to remove the plasma from the samples and the 
plasma was then stored in 2ml cryovials (Nalge) ,  at - 70°C in a freezer for 
further analysis. Five volumes of 0 .9% buffered NaCI solution were added using 
a 5 .0  x 1I10ml disposable pipettes (Fisher) .  The samples were centrifuged and 
supernatant fluid was removed by Pasteur pipette . The RBC were washed 
three times in this manner. 
A continuously (Ranin) adj ustable microliter pipette was used to add the 
suspended RBC to 0 .9% phosphate buffered saline, this was done in triplicate 
for each sample.  In two 16 x 100mm disposable culture tubes ( Fisher) 0 . 25ml 
of the RBC suspension was then added to 2% H 2 0 2 solution using an 
adjustable pipette . The RBC suspension was added to 0 .9% phosphate buffered 
saline to determine any initial RBC hemolysis. The samples were incubated 
and gently shaken in a water bath shaker (Eberbach Corporation Ann Arbor, 
Mi .) .  
Distilled w ater was added to the solution in one 1 00mm disposable 
culture tube and 0 .9% phosphate buffered saline was added to the other two 
culture tubes. Samples were mixed using a Vortex, and were centrifuged with 
an IEC clinical centrifuge ( International Equipment Co . ,  Needam Hts. ,  MA. ) .  
Absorbance was determined using a Spectronic 20D (Milton Ray Co. ) and B&L 
cuvettes.  Hematocrit was measured to determine the percent of RBC per 
volume. 
d. Procedure 
Blood samples from both experimental groups were collected in 
heparinized tubes, were centrifuged and plasma was removed.  The RBC were 
then washed three times with 5 volumes of 0 .9% saline solution. Following the 
third wash, O .4ml of packed RBC was added to 9.6ml 0 . 9% phosphate buffered 
saline at pH 7 . 4, creating a 4% suspension of RBC.  In two separate culture 
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tubes, tube # 1  and tube #2,  0 . 25ml of the 4% RBC suspension was added to 
0 .25ml of 2% H202 . In a third tube, tube #3, 0 .25ml of the 4% RBC suspension 
was added to 0 .25ml distilled water. 
The samples were incubated for 3hr at 37°C with gentle shaking. After 
incubation, 4 . 5ml of 0 .9% phosphate buffered saline was added to tube # 1  to 
determine hemolysis resulting from H202 . In tube #2, 4. 5ml distilled water 
was added to determine 100% hemolysis .  Finally, in tube #3,  4 . 5 ml  0 .9% 
phosphate buffered saline was added to determine how much hemolysis existed 
before the addition of H202. 
All samples were mixed and centrifuged for six minutes . The RBC pellet 
accumulated at the bottom of the culture tube with the hemoglobin in solution. 
A sample of the supernatant fluid was transferred to a cuvette with a Pasteur 
pipette and the absorbance was determined at 540nm. 
e. Calculations 
1. Percent Hemolysis for HPT 
The 100% hemolysis value was obtained from the absorbance of tube 
#2, the tube with H202 added before incubation and distilled water added after 
incubation. A value for the hemolysis due to the H202 was determined by the 
absorbance of tube # 1 ,  which had H202 added before incubation and 0 . 9% 
phosphate buffered NaCI added after incubation. To calculate the percent 
hemolysis of the RBC in the HPT, the value for hemolysis due to H202 (tube 
# 1) was divided by the 100 % hemolysis value (tube #2) and then multiplied by 
100.  A mean % Hemolysis was determined for all rat and human samples for 
the HPr and are shown in Table 10. 
2. Percent Hemolysis With Increasing Hypotonic NaCI 
Environment 
Percent hemolysis was determined for both the human and rat samples 
using the assay for determination of RBC hemolysis with decreasing hypotonic 
NaCI environment and the appropriate calculations as described above . A 
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graph was then drawn with the ordinate % Hemolysis and the abscissa %NaCl . 
The 50% hemolysis value was interpolated from the graph. Figures 12  and 13 
represent examples of 50% hemolysis graphs for a human sample and a rat 
sample .  Table 9 presents mean %NaCI concentrations for 50% RBC hemolysis 
for all samples in the HPJ'. All calculations were performed using Cricket 
Graph software . 
3. Correlation Analysis 
The %N aCI for 50% hemolysis versus %Hemolysis as calculated in the 
HPT for each human sample was correlated on a linear correlation graph, 
shown in figure 14, with the ordinate 50% hemolysis and abscissa %H202 (37) .  
The %N aCI for 50% hemolysis versus %Hemolysis as calculated in the HPT 
for each animal, NX, PF, and SH, was graphed on a linear correlation graph, as 
shown in figure 15 ,  with the ordinate 50% hemolysis and the abscissa %H202. 
All analyses were performed using Cricket Graph and Statstix software. 
4. Assay for Vitamin E Quantitation- HPLC method 
Plasma samples were obtained from Sprague-Dawley experimental rats 
and from the five human subj ect samples studied in the HPT.  The blood 
samples were centrifuged for 5 min at 1000 x g and the plasma removed and 
placed in 2ml cryostat tubes. Plasma samples were stored at -70°C freezer 
until used for analysis . 
a. Extraction Procedure (38) 
The samples were thawed for analysis and a 250J..lI aliquot was added to 
a 1 7  x 1 2 5mm screw cap tube.  750J..lI of 1% sodium ascorbate and 2 . 0ml 
absolute ethanol was added to the sample. The samples were mixed for 30 sec 
and allowed to remain shielded from the light for 5 min. To extract the vitamin 
E 5ml n-hexane was added. As an internal standard, 20J..lI of ethyl-B-apo-8-, 
carotenoid was added . The tubes were then covered with foil , capped, mixed for 
1 . 5 min and centrifuged for 10 min at 1000 x g. A 4 .0ml aliquot of the hexane 
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layer was removed from the samples and placed in conical bottom 17 x 1 18mm 
tubes . In a 40°C water-bath using a stream of nitrogen, the hexane layer was 
evaporated .  The oily residue was dissolved in 1 .0ml of the mobile phase and 
200�1 was inj ected onto a high performance liquid chromatography (HPLC) 
column (38) .  
h. HPLC Procedure 
HPLC was performed at room temperature with a Waters model 
5 10 pump and Waters model 490 programmable multiwavelength detector at 
292 nm at a flow rate of 1 . 5  ml!min. Data was collected using a Shimadzu CR 
50 1 integrator. Separation was performed on a Supercosil LC- 18 25 cm 
column with a Waters Guard-Pak u-Bondapak pre column module .  The 
standard mobile phase was 80 :20 methanol :toluene, which had been filtered 
and degassed. All solvents were HPLC grade and were from Fisher Scientific. 
Vitamin E standards were obtained from Sigma Chemical Co . ,  St. Louis, MO. 
All of the standards were initially dissolved in 50:50 methanol:toluene and were 
diluted to appropriate concentrations with the 80 : 20 mobile phase.  
Concentrations of the standards were determined spectrophotometrically 
using an extinction coefficient ( E 1 % ) of 2494 at 292 nm for AT. Variable 
amounts of the standards (4-30 ng) were inj ected into the column and 
integration was performed on the resultant peak areas . Standard curves (area 
versus amount inj ected) were prepared for AT and the concentration of the 
sample components was calculated from these standard curves in �g/dL . The 
spectra scans for the samples showed that the AT spectra were virtually 
identical between the standards and the plasma samples . The retention times 
of the sample peak agreed with those of the standards . An AT standard was 
also determined daily to adjust the retention time within the programmed 
analysis C± 5 seconds). 
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Results 
A Red Blood Cell stability in Uremic Rats Study 
The female Sprague-Dawley rats used in this experiment were divided into 
three separate experimental groups. As shown in Table 2 ,  animals that 
received a five-sixth nephrectomy and had no dietary restrictions were placed 
in the NX group. Animals that received surgery, but no tissue was removed 
and had no dietary restrictions were placed in the SH group . Finally, animals 
that received surgery, but no tissue was removed and had dietary restrictions 
were placed in the PF group. Samples were collected in four trials . Initial 
samples, taken from the animal two weeks following surgery and final samples, 
taken as the animal was sacrificed, were obtained in Trial I and Trial I I I .  Only 
initial samples were used in Trial II and in Trial IV, only final samples were 
analyzed.  The animals were weighed at the time of sampling and individual 
weights of each animal and the mean wieght of the animals in each trial are 
given in Table 6, along with the mean values for each group. 
1. Determination of RBC Hemolysis With Increasing Hypotonic 
NaCI Enviroment 
For each sample in every trial, the percent hemolysis was calculated and 
graphed. In order to calculate the %Hemolysis, the optical density (OD) for the 
0 .8  (A) buffered NaCI solution was subtracted from the OD of the remaining 
concentrations of buffered %NaCI solutions; 0 .60 ( B ), 0 . 50 (C ), 0 .475(D) ,  0 .45 
(E), 0 .40 (F), 0 . 25 (G) and O . lO(H) .  The values for A, B ,  C ,  D, E,  F, G and H 
were then divided by the value obtained for H (which represents OD for 100% 
hemolysis) and multiplied by 100 to determine percent hemolysis . 
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Table 6 .  B ody Weight of Animals at Time of Sampling a 
Trial I Trial n Trial ill Trial IV 
2 3 5  2 0 7  226 208 
258 202 230 238 
2 18 22 1 240 203  
268  2 12 223  204  
244 1 99 2 18 2 2 2  
2 6 8  2 1 5  2 14 180 
274 2 0 1 197  2 16 
280 207 23 1 2 3 1  
256 186 234 2 24 
289 207 243 233  
245 227 2 14 206  
23 1 205 228 2 1 5  
2 7 0  2 1 7 232 22 1 
254  250  242 238 
2 7 8  230  203  204 
2 7 1 2 1 3  2 3 1  259  
280  2 1 2 2 1 2  2 2 2  
2 9 6  234  239 227  
295  259  222  208  
286 234 202 182  
283 2 2 1  2 1 7  2 3 5  
3 2 3  2 16 2 3 7  1 9 9  
2 3 7  232  2 5 7  
240 2 18 2 3 7  
2 5 1 255  2 1 3 
208  246 1 9 7  
2 2 8  2 5 6  
228  2 1 7 
268 (5 . 19 ,  22)b 220 (3 .28, 28)C 226 (2 .81 ,  26)
d 220 (3 .83, 28)e 
a Values for body weight of experimental animals is give in grams 
b Mean (+/-SEM, 22) 
c Mean (+/-SEM, 28) 
d Mean (+/-SEM, 26) 
e Mean (+/- SEM, 28) 
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For all samples, graphs were drawn with the ordinate, %Hemolysis as 
calculated above and the abscissa %N aCI concentrations. The 50% hemolysis 
point was interpolated from the graph. Figure 3 is an example of a NX initial 
sample from Trial III ,  and the %N aCI concentration at 50% hemolysis of the 
RBC was determined to be 0 .420 .  Figure 4 is an example of the graph of 
%Hemolysis versus %NaCI concentration for a PF initial sample from Trial II ,  
%NaCI concentration at 50% hemolysis of the RBC was found to be 0 .4 10 .  
Figure 5 is  an example of the graph obtained for a SH initial sample from Trial 
I I ,  the %NaCI concentration at 50% hemolysis of the RBC is 0 .420 . Similar 
graphs were drawn with the ordinate, %Hemolysis as calculated above and the 
abscissa, %N aCI concentrations for the final samples of all animals in every 
trial . The 50% hemolysis point was interpolated from the graph. Figure 6 is an 
example of a graph for NX final sample from Trial I I I ,  the %N aCI 
concentration at 50% hemolysis of the RBC is 0 .430 . Figure 7 is a graph for a 
PF final sample from Trial I I I ,  the %NaCI concentration at %50 hemolysis of 
the RBC is 0 .450.  Figure 8 is a graph of a SH final sample from Trial III, the 
%NaCI concentration at 50% hemolysis for the RBC is 0 .430.  
The 50% hemolysis points obtained from the %N aCI concentration 
versus %Hemolysis graphs were averaged using Statstix software within each 
animal group and Trial . These results were then grouped as to initial or final 
sample and Table 7 shows the mean %N aCI concentration from these graphs 
at 50% RBC hemolysis for all four trials. 
Linear correlation graphs were constructed for every sample in each 
Trial . Buffered %N aCI concentrations versus %Hemolysis of the RBC were 
correlated.  The linear regression equation obtained from the correlation graphs 
provides the linear coefficient "r" and an equation that allows for the 
calculation of %N aCI concentration at 0% hemolysis .  Figure 9 is an example of 
the linear correlation graph obtained for SH initial samples in Trial I, the 
correlation coefficient was found to be 0 .93 1,  which is significant at the p<0.05 .  
Figure 10 is a linear correlation graph of PF initial samples in Trial I and the 
correlation coefficient was found to be 0 .93 1,  which is significant at p<0 .05 .  
Figure 11  is an example of a linear correlation graph for NX initial samples in 
Trial I and the correlation coefficient was found to be 0.730, which is significant 
at p<0.05 .  Linear correlation graphs such as these were done for every sample .  
Figure 3 
% Hemolysis versus the %NaCI concentration. Mean 
data for NX initial samples Trial II .  
%NaCI concentration at 50% hemolysis is extrapolated 
from the graph and is 0 .420. 
The error bars are the SEM. 
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Figure 4 
Percent hemolysis versus the %NaCI concentration. Mean 
data for PF initial samples Trial II .  
%NaCI concentration at 50% hemolysis is extrapolated 
from the graph and is 0 .410 .  
The error bars are the SEM. 
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Figure 5 
Percent hemolysis versus the %NaCl concentration. Mean 
data for SH initial samples Trial II .  
%NaCl concentration at 50% hemolysis is extrapolated 
from the graph and is 0.420. 
The error bars are the SEM. 
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Figure 6 
Percent hemolysis versus the %NaCl concentration. Mean data 
for NX final samples Trial III .  %NaCl concentration at 50% 
hemolysis is extrapolated from the graph and is equal to 0 .430 .  
The error bars are the SEM. 
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Figure 7 
Percent hemolysis versus the %NaCI concentration. Mean 
data for PF final samples Trial III .  
%NaCI concentration at 50% hemolysis is extrapolated 
from the graph and is 0 .450. 
The error bars are the SEM. 
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Figure 8 
Percent hemolysis versus the %NaCI concentration. Mean 
data for SH final samples Trial III .  
%NaCI concentration at 50% hemolysis is extrapolated 
from the graph and is found to be equal to 0 .430. 
The error bars are the SEM. 
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Table 7 .  Mean %NaCI Concentration for 50% Red Blood Cell Hemolysis for 
Trials I ,  I I ,  I I I  and IV as Determined by Interpolation of the %NaCI 
Concentration Versus %Hemolysis Graphs 
Protocol Initial 
NX 0 .4 14 ( .00 1 ,  16) 0 .417  ( . 005, 25) 
PF 0 .412  ( .004, 28) 0 .422 ( .006, 35) 
S H  0 .4 16 ( .005, 19)  0 .420 ( .004, 29) 
a Mean C+I- SEM, N),  not significantly significant from each other at p>0 .05.  
Figure 9 
%NaCI concentration versus %Hemolysis of RBC for 
SH initial animals in Trial 1 .  
The linear regression equation is: 
y= 0 . 181  x 10-3X + 0. 582 R2=0.867 
The R value for the plot is significant for an N =8 showing 
a linear relationship for these parameters. 
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Figure 10 
%NaCI concentration versus %Hemolysis of RBC for 
PF initial animals in Trial I .  
The linear regression equation is: 
y= 0 .39 1  x 10-3 X+ 0 .568 R2=0. 867 
The R value for the plot is significant for an N=7 showing 
a linear relationship for these parameters . 
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EI 3 PF (i) 
• 1 1  PF (i) 
• 17 PF (i ) 
@ 18 PF (i) 
� 2 1  PF (i) 
o 24 PF (i ) 
26 PF (i) 
Figure 1 1  
%NaCI concentration versus %Hemolysis of RBC for 
NX initial animals in Trial I .  
The linear regression equation is : 
y= 0 .370 x 10-3 X + 0. 533 R2=0 .533 
The R value for the plot is significant for an N =7 showing 
a linear relationship for these parameters . 
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iii 6 NX (i) 
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• 8 NX (i) 
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To calculate the %N aCI concentration for 0% and 50% hemolysis, the 
equation y= b + m e- 3 x was used.  Column one of Table 8 represents the 
concentraion of buffered %NaCI when the x axis is equal to zero, i . e .  0% 
hemolysis of RBC for all animal samples. Column two of Table 8 lists the 
concentrations of buffered %NaCI when the x axis is equal to fifty, i .e .  50% 
hemolysis of RBC for all animal samples . Using the equation y= b + m e-3x, the 
x intercept was placed at zero or 50 as described above and b and m were , 
obtained from the linear correlation graphs (example figures 9- 1 1 ) .  Column 
three of Table 8 lists the concentration of buffered %N aCI for 50% hemolysis 
as calculated from the %Hemolysis versus %N aCI concentration graphs for all 
animal samples (example figures 3-8). 
The %N aCI concentration for 0% hemolysis as determined from the 
linear correlation graph indicates a significant difference between; the NX (i ) 
and NX (f) samples in Trial I, the NX (i) and SH (i) samples in Trial II and the 
NX (i) and NX (f) and SH (i) and SH (f) samples in Trial III .  The %N aCI for 50% 
hemolysis as obtained from the linear correlation graphs indicated a significant 
difference between; the NX (i) and NX (f) samples in Trial I and the NX (i) and 
NX (D samples in Trial I I I .  The %N aCI concentraion for 50% hemolysis as 
determined from the %Hemolysis versus %NaCI graphs indicated a significant 
difference between; the NX (i) and NX (f) samples in Trial III and the SH (i) and 
SH (f) in Trial III .  
B. Red Blood Cell Hemolysis Peroxide Test 
The H PT was performed on two separate groups of samples . The 
experimental animals from Trial IV of the RBC Stability in Uremic Rats Study 
were used and therefore consisted only of samples taken at the time of , 
sacrifice . The second group of blood samples were from five adult female 
humans; A, B ,  F, G, H .  The modified Parpart procedure (8,  9, 34, 35)  as 
described in Methods was also performed on these same samples. Figure 12 is 
an example of the %NaCI concentration versus %Hemolysis for a human 
sample in the H PT.  The %NaCI concentration at 50% hemolysis for human 
sample H was calculated from the graph and is 0.4 10.  Figure 13 is an example 
of the %N aCI concentration versus %Hemolysis for a SH rat sample in the 
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Table 8 .%�aCI for 0% Hemolysis and 50% Hemolysis as Described by Linear 
Correlation Graphs and %N aCI for 50% Hemolysis as Decribed by N aCI 
Graphs 
Protocol 
Trial I 
NX (i) 
NX (f) 
SH (i) 
SH (f) 
PF (i) 
PF (f) 
Trial n 
NX (i) 
SH (i) 
PF (i) 
Trial ill 
NX (i) 
NX (f) 
SH (i) 
SH (f) 
PF (i) 
PF (f) 
Trial IV 
NX (f) 
SH (f) 
PF (f) 
% NaCI for OO/dl,b 
Hemolysis Linear 
Correlation 
0 .533 (0 .0 16, 7 )  
0 . 6 1 6  (0 .0 15,  7 )  
0 . 582 (0 .0 13 ,  8 )  
0 .603 (0 .023,  8 )  
0 .568 (0 .0 14, 7 )  
0 . 561  (0 .0 19, 7 )  
0 . 593 (0 .009, 9 )  
0 .63 1 (0 .02 1 ,  8 )  
0 . 6 1 1 (0 .022,  9 )  
0 .586 (0 .007,  3 )  
0 .674 (0 .040, 5 )  
0 . 6 10 (0 .026, 3 )  
0 .638 (0 .038, 4)  
0 .640 (0 .0 18, 12)  
0 .665 (0 .0 15, 15)  
0 . 583 (0 .005, 9 )  
0 . 586 (0 .004, 9) 
0 .584 (0 .005, 10)  
a Mean (+1- SEM, N )  
%NaCI for 50% %NaCI for 50% Hemolysis 
Hemolysis Linear Graphical Interpolationa,d 
Correlationa,c 
0 .370 (0 .0 14, 7)  0 . 4 14 (0 .0 1 1, 7 )  
0 .407 (0 .006, 7 )  0 .423 (0 .005, 7 )  
0 .410 (0 .009, 8 )  0 .417  (0 .007 ,  8 )  
0 .395 (0 .0 15,  8) 0 .430 (0 .007,  8) 
0 .391  (0 .0 12,  7)  0 .408 (0 .0 10, 7)  
0 .386 (0 .007,  7)  0 .405 (0 .002, 7 )  
0 .387 (0 .007,  9) 0 .416 (0 .002, 9) 
0 .399 (0 .009, 8) 0 .422 (0 .008, 8) 
0 .397 (0 .0 19, 9) 0 .4 1 1  (0 .006, 9) 
0 .377 (0 .002, 3 )  0 .4 1 1  (0 .00 1 ,  3 )  
0 .439 (0 .03 1 ,  5 )  0 .430 (0 .002, 3 )  
0 .381  (0 .0 18, 3 )  0 .397 (0 .009, 4)  
0 .432 (0 .044, 4)  0 .439 (0 .002, 4)  
0 .4 10 (0 .0 1 1 , 12 )  0 .436 (0 .008, 12 )  
0 .433 (0 .0 1 1 , 15 )  0 .448 (0 .008, 15 )  
0 .379 (0 .005, 9) 0 .408 (0 .007, 9)  
0 .376 (0 .004, 9 )  0 .397 (0 .006, 10)  
0 .377 (0 .006, 10)  0 .407 (0 .005, 9 )  
b The concentration o f  buffered %NaCI when the x axis i s  equal t o  zero, i . e .  0 %  hemolysis o f  RBC ,  
calculated from linear correlation graphs for all animal samples, example figures include, figures 9-
1 1 .  
c The %NaCI concentration when the x axis is equal to 50, i .e .  5 0% hemolysis of RBC, calculated 
from linear correlation graphs for all animal samples, example figures include, 9- 1 1 .  
d The %NaCI concentration a t  50% hemolysis calculated from %Hemolysis versus %NaCI 
concentration graphs for all animal samples, example figures include 3-8 .  
Figure 12 
%Hemolysis versus the %N aCI concentration 
data for Human sample H in the HPI'. 
%NaCI concentration at 50% hemolysis is calculated 
from the graph and is 0 .410 .  
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Figure 13 
%Hemolysis versus %N aCI concentration 
data for SH rat sample in the HPT. 
%NaCI concentration at 50% hemolysis is calculated 
from the graph and is 0 .410 .  
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H PT. The %NaCI concentration at 50% hemolysis for the SH animal was 
calculated from the graph and is 0 .410.  Similar graphs were constructed for PF 
and NX animals. 
The mean %N aCI concentration at 50% hemolysis for the PF animals 
was calculated from the graphs and is 0 .397, the mean %NaCI concentration 
at 50% hemolysis for NX animals was calculated from the graphs and is 0 .408 
and the mean %N aCI concentration at 50% hemolysis for SH animals was 
calculated from the graphs and is 0 .407 .  Table 9 lists the mean %N aCI 
concentrations for 50% hemolysis for all samples used in the HPT experiment. 
There is a significant difference between the PF samples and the NX samples 
as well as between the PF samples and the SH samples. 
To calculate the percent hemolysis of the RBC in the H PT, the 100% 
hemolysis value was divided into the value for hemolysis due to the H PT and 
multiplied by 100 .  The 1 00% hemolysis value was obtained from the 
absorbance of tube #2, the tube with H202 added before and after incubation. 
A value for the hemolysis due to the HPT was determined by the absorbance of 
tube #1 ,  which had H202 added before incubation and phosphate buffered 0 .9% 
N aCI added after incubation. Table 10 gives the mean %Hemolysis for the NX, 
PF, SH and human samples used in this experiment. No significant difference 
was found between the rat samples . 
Linear correlation graphs were drawn for both the rat and human samples. 
Figure 14 is a linear correlation graph of the %NaCI for 50% hemolysis versus 
the %Hemolysis as calculated from the HPT for all human samples. A linear 
regression equation, y=3. 529 x 10-4X + 0 .406, was obtained from the linear 
correlation graph and the correlation coefficient was determined to be 0 .607, 
which is not significant at p<0 .05 for a sample size of five . Figure 15 is a linear 
correlation graph of %N aCI for 50% hemolysis versus the %Hemolysis as 
calculated from the H PT for all rat samples. A linear regression equation, 
y=0. 44 1  x 10-3X + 0 .479, was obtained from the linear correlation graph and 
the correlation coefficient was determined to be 0 .4 12,  which is significant at 
p<0.05 for a sample size of 28 . 
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Table 9.  %NaCI for 50% Red Blood Cell Hemolyis for all Rat Samples used in 
the HPT Experiment 
Protocol Final a 
NX 0 .408 (0 .007,  9) 
PF 0 .397 (0.00 1 ,  10) 
SH 0 .407 (0 .003 ,9) 
Human 0 .399 (0 .002, 5)  
a Mean ( +/- SEM, N) ,  values obtained by procedure varying NaCI 
concentration. 
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Table 10. %Hemolysis for HfYI' Experiment 
Protocol % Hemolysisa, b, c 
NX 1 1 .0 ( 1 .87, 9) 
PF 10. 1 ( 1 .60, 10) 
SH 1 1 .6 (0 .83,  9) 
Human 37 .6  (7 .7 1 , 5) 
a Mean (+1- SEM, N) 
b %Hemolysis=(Hemolysis of sample with H202 X 100)/100% Hemolysis 
sample 
c No significant difference was found between the rat experimental groups 
Figure 14 
%N aCI for 50% hemolysis versus the %Hemolysis 
as calculated from the HfYI' for all human samples .  
The linear regression equaton is : 
y= 3 .529 x 10-4X +0 .406 R2= 0 . 368 
The R value for the plot was not significant for an N =5 showing 
no linear relationship for these parameters . 
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Figure 15 
%NaCI for 50% hemolysis versus the %Hemolysis 
as calculated from the HPT for all rat samples . 
The linear regression equation is: 
y= 0 .44 1 x 10-3X +0.479 R2= 0 . 170 
The R value for the plot is significant for an 
N =28 showing a linear relationship for these parameters. 
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C. Vitamin E Concentration 
Plasma was collected from the five human and from experimental 
animal samples. The plasma collected from the human samples was analyzed 
for vitamin E concentration by HPLC . Table 1 1  lists the vitamin E 
concentration for each human serum sample.  A linear correlation graph of 
serum vitamin E concentration versus %NaCl concentration for 50% 
hemolysis for the human samples was constructed and is shown in figure 16.  
The linear correlation coefficient was calculated to be 0 . 283 and is not 
significant at p<0 .05 for a sample size of five. All of the vitamin E values are 
within normal range with the mean value for the five samples of 6861lg/dL +/-
122 SEM. 
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Table 1 1 . Plasma Vitamin E Concentrations and %N aCI for 50% Hemolysis 
points for Human Samples 
Protocol Plasma Vi tamin E a, b %N aCI for 50% Hemolysis C 
A 106 1 0 .4 18 
B 859 0 .430 
F 3 7 7  0 .409 
G 6 16 0 . 329 
H 5 19 0 .4 10 
a Serum Vitamin E concentrations expressed in �dL 
b Mean +/- SEM, 5 
c Mean +/- SEM, 5 
Figure 16 
Serum vitamin E concentrations versus %NaCl for 
50% hemolysis for human samples � B, F, G, H in the HPT. 
The linear regression equation is: 
y=- 1929X + 83 .9 R2=0 .080 
The R value for the plot is not significant for an 
N=5 showing no linear relationship for these parameters . 
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Discussion 
A Red Blood Cell Stability in Uremic Rats Study 
1. Weight and Gender Considerations of the Research Animals 
The animals used in this study were female Sprague-Dawley rats . The 
individual weights of each animal and the mean weights of the animals in each 
trial at the time of sampling are shown in table 6 of the Results Section. The 
mean weight of the animals in Trial I at the time of sampling was 268g with a 
SEM of 5 . 19 .  The mean weight of the animals in Trial I I  at the time of 
sampling was 220g with a SEM of 3 .28  The mean weight of the animals in 
Trial I I I  at the time of sampling was 226g with a SEM of 2 .8 1 .  The mean 
weight of the animals in Trial IV at the time of sampling was 220g with a SEM 
of 3 .85 .  The mean weight of the animals in Trial I was significantly higher than 
that of the animals in Trials II ,  I I I ,  or IV. The mean weights for the animals in 
Trial II ,  I I I  and IV were not significantly different than each other. Whether or 
not any discrepancies in weight or the fact that all the animals were female 
played a role in RBC stability is unclear. Future studies will include samples 
from male rats as well as a study utilizing both female and male rat blood 
samples with no significant weight differences among the animal groups. 
When the animals arrived at the laboratory, the mean weight for 
the animals in Trial I was 182g, the mean weight for the animals in trial II was 
109g, the mean weight for the animals in Trial III  was 175g and the mean 
weight for the animals in Trial IV was 160g. These weights are significantly 
lower than the mean weights of the animal groups at the time of sampling. 
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Sampling occured approximately four weeks after the animals arrived at the 
laboratory and approximately two weeks after surgical procedures were 
performed. Further research into the metabolic effects of stress on animals 
would be of interest. 
2. Determination of RBC Hemolysis With Increasing Hypotonic 
NaCI Environment 
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The mean buffered %NaCI concentration at 50% hemolysis was 
determined for the NX, PF and SH samples from all four Trials for both the 
initial and final samples, these results are shown in Table 7 in the Results 
Section. No significant difference in the mean %NaCI concentration at 50% 
RBC hemolysis was found between the initial and final samples within any of 
the three groups . No significant difference in the mean %NaCI concentration at 
50% RBC hemolysis was found for the initial samples between groups and no 
significant difference was found for the mean %NaCI concentration at 50% 
RBC hemolysis for the final samples between groups. Table 12  outlines the T­
statistics calculated from the mean %NaCI concentration at 50% hemolysis 
for the initial and final samples from Table 7 and compares them in three 
different ways. First, mean %NaCI concentration for the initial samples were 
statistically compared between animal group, i . e . ,  the mean %NaCI 
concentration for the initial samples of the PF animals was compared to the 
%NaCI concentration for the initial samples of the SH animals.  Secondly, 
mean %N aCI concentration for the final samples were statistically compared 
between animal group and finally, the %NaCI concentrations for the initial and 
final samples were statistically compared. From these data there was found to 
be no significant difference between or among these sample groups. 
This leads to the conclusion that, under the circumstances outlined in 
this study, RBC of uremic animals (NX) are niether more or less stable to 
hypotonic shock than are RBC of the animals who underwent the five-sixth 
neprectomy procedure, but did not have any tissue removed, regardless of any 
dietary constrictions (SH and PF). Decreased stability of the RBC in renal 
failure as discussed inthe Objectives Section has not been shown to be evident 
in this group of animals. 
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Table 12 .  T- Statistics for Mean %NaCI at 50% Hemolysis for all Four 
Trials 
Comparison 
Group 
t-Stats 
Initial vs . initial between samples 
PF (i) vs. SH (i) -0 .54 
PF (i)  vs . NX (i) -0 .20 
NX ( i )  vs .  SH (i) -0 .45 
Final vs . Final between samples 
PF (D vs. SH (D 0 . 29 
PF (D vs. NX (D 0 . 55 
NX (D vs. SH (D -0 .40 
Initial vs. Final same sample 
PF (i) vs. PF (D - 1 . 2 1  
NX (i) vs. NX (D -0 .59 
SH ( i )  vs . SH (D -0 .62 
45 
4 2  
3 3  
6 2  
5 8  
5 2  
6 1  
3 9  
46 
Degree 
Freedom 
Significance 
0 . 591  
0 . 846 
0 . 654 
0 . 775  
0 . 587 
0 . 689 
0 . 23 1 
0 . 557 
0 . 537 
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Analytic precision experiments using multiple assays of the same blood 
sample for 50% RBC hemolysis showed a coefficient of variation of 1 . 1% for 
the procedure used to determine RBC stability to hypotonic shock as described 
in the Methods Section. 
Linear correlation graphs were constructed using initial and final 
samples from all four trials . The %NaCI at 50% hemolysis was determined 
from the %Hemolysis versus %NaCI concentration graphs for all samples. The 
equation y 
= 
b + m e-3x was used to calculate the %N aCI concentration at 0% 
hemolysis and at 50% hemolysis. Table 8 in the Results section summarizes 
these findings. 
The %NaCI concentration for 0% hemolysis was significantly higher for 
the NX (D sample as compared to the NX (i) sample in Trial I .  The %N aCI 
concentration for 50% hemolysis as obtained from th linear correlation graph 
was also signiicantly higher for NX (D as compared to NX (i) in Trial I .  One 
purposed explanation for the increased stablilty of RBC of the initial samples 
as compared to the RBC in the final samples is that as uremia progresses, the 
RBC may become increasingly unstable .  
A significant difference in %N aCI concentration for 0% hemolysis was 
also found between the NX (i) and SH (i) samples in Trial II .  The SH (i ) sample 
appears more stable,  the high SEM of this sample (0 .02 1) ,  makes this data 
point less reliable .  
Finally, in  Trial I I I  the NX (i) and NX (D %NaCI concentrations were 
significantly different in every catagory, The decreased sample size in for the 
NX animals in Trial II may explain these data, in the future a larger sample 
size will be used to analysis this data. Also in Trial III ,  the SH (i) and SH (f) 
%NaCI concentrations were significantly different for the %NaCI for 0% 
hemolysis as well as the %N aCI for 50% hemolysis as determined from 
%Hemolysis versus %NaCI concentraion graphs. Again the small sample size 
may explain this difference. 
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B .  Red Blood Cell Hemolysis Peroxide Test 
The HPT was performed on animal samples from Trial IV of the 
RBC Stability in Uremic Rats Study and on five human samples in order to 
demonstrate an alternate method by which to determine RBC hemolysis.  For 
each sample absorbance at 100% hemolysis was determined as well as 
hemolysis due to the 2% solution of H202. The %Hemolysis of the RBC was 
determined by dividing the hemolysis due to the H202 by the 100% hemolysis 
value and multiplying by 100. 
Table 10 in the Results Section presents the mean %Hemolysis values 
for the NX, PF, SH and Human samples used in the HPT. The mean hemolysis 
points for the HPT for all animal samples were statistically analysed and 
compared to each other in a standard student's t-test as shown in Table 13 . 
There was no significant difference between the animal samples.  This is 
consistent with the findings in the RBC Stability in Uremic Rats Study, no 
significant difference was found between the animals for the %N aCI 
concentration at 50% hemolysis (as discussed in the Determination of RBC 
Hemolysis With IncTeasing Hypotonic NaCI Environment Section). 
In addition to the HPT, the modified Papart procedure as described in 
the Methods Section, was also performed on these samples. Table 9 lists the 
mean %NaCI concentrations for 50% RBC hemolysis for all the samples in the 
HPT.  Although the PF mean %NaCI concentration for 50% hemolysis is 
significantly different form both the SH and NX samples, when analysed with 
data from all four trials, no significant difference between the PF and SH or NX 
animals is found. 
Linear correlation graphs were constructed in order to compare the 
correlation between the HPT method of determining RBC hemolysis and the 
determination of RBC hemolysis with an increasing hypotonic NaCI 
environment. Figure 14 in the Results Section is a comparison of the %NaCI 
concentraion at 50% hemolysis versus the %Hemolysis as determined by the 
HPT for the human blood samples. The correlation coefficient was 0 .607 which 
is not significant at a p<0.05 for a sample size of five. Future research should 
include more human samples in order for such a comparison to be significant. 
Figure 15 in the Results Section is a comparison of the %NaCI concentraion at 
Table 13 .  T- Statistics for All H202 Trials 
Comparison 
Group 
Between samples 
SH (f) vs. PF (f) 
NX (f) vs. PF (f) 
SH (f) vs. NX (f) 
t-Stats 
0 .787 
0.364 
0 .284 
Degree of 
Freedom 
1 7  
1 7  
1 6  
Significance 
0 . 442 
0 . 720 
0 . 780 
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50% hemolysis versus the %Hemolysis as determined by the HPT for the 
animal blood samples. The correlation coefficient was 0 .4 12 which is significant 
at a p<0 .05 for a sample size of 28.  Consequently, for the larger sample size, 
the findings for the HPT method for determining RBC stability and the findings 
for the determination of RBC hemolysis with an increasing hypotonic NaCI 
environment are comparitively similar . Future research will expand the HPT 
method to all samples . 
c. Vitamin E Analysis 
Five human serum samples were analysed using the HPLC method. 
Figure XIV in the Results Section outlines the vitamin serum E concentration 
in each sample and the 50% hemolysis point for each sample . The linear 
correlation graph of serum vitamin E concentration versus %Hemolysis, 
(figure XVI in Results section), with a correlation coefficient of 0 .283, shows no 
significant relationship between serum vitamin E concentration and 
%Hemolysis in these samples. 
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